NCT05067244View on ClinicalTrials.gov

A Phase 2 Open-Label Treatment Development Study of MDMA-Assisted Cognitive Processing Therapy (CPT) for Posttraumatic Stress Disorder (PTSD)

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 4, 2021

Primary Completion Date

November 1, 2024

Study Completion Date

November 1, 2024

Conditions
Post Traumatic Stress Disorder
Interventions
DRUG

MDMA

MDMA assisted psychotherapy

Trial Locations (1)

M6G 1L5

Remedy Institute, Toronto

All Listed Sponsors
collaborator

Multidisciplinary Association for Psychedelic Studies

OTHER

lead

Remedy

INDUSTRY

NCT05067244 - A Phase 2 Open-Label Treatment Development Study of MDMA-Assisted Cognitive Processing Therapy (CPT) for Posttraumatic Stress Disorder (PTSD) | Biotech Hunter | Biotech Hunter